I think it is for most patients and payers if it comes at significant reduction in length of therapy / cost. If Abbvie can produce 99% but it is not 8w and/or you need to see if they are cirrhotic and treat longer, then I think we may end up replaying the Harvoni vs. Viekira scenario - people take ease-of-use and convenience over minor advantages in efficacy when we are at these extremely high levels already.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.